You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 7, 2025

CUROSURF Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Tradename: CUROSURF
Recent Clinical Trials for CUROSURF

Identify potential brand extensions & biosimilar entrants

SponsorPhase
NorthShore University HealthSystemPhase 4
Chiesi USA, Inc.Phase 4
University College, LondonPhase 1

See all CUROSURF clinical trials

Pharmacology for CUROSURF
Mechanism of ActionSurfactant Activity
Physiological EffectAlveolar Surface Tension Reduction
Established Pharmacologic ClassSurfactant
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for CUROSURF Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for CUROSURF Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for CUROSURF Derived from Patent Text Search

These patents were obtained by searching patent claims

Market Dynamics and Financial Trajectory for the Biologic Drug: CUROSURF

Introduction

CUROSURF, also known as poractant alfa, is a biologic surfactant used in the treatment of Respiratory Distress Syndrome (RDS) in premature infants. This article delves into the market dynamics and financial trajectory of CUROSURF, highlighting its dominance, usage, and economic impact.

Market Dominance of CUROSURF

CUROSURF has been the leading surfactant in the United States for over a decade. It is widely used by neonatal intensive care units (NICUs) across the country, with over 85% of top neonatology hospitals preferring CUROSURF[1].

Global Market Share

CUROSURF holds a significant global market share among US FDA-approved surfactants. It is available in 97 countries, making it one of the most widely used surfactants globally. In contrast, other surfactants like Infasurf are available in only 25 countries[1].

Hospital Adoption and Retention

The adoption rate of CUROSURF by hospitals is impressive, with a 500+ percent increase in usage since 2009. Many hospitals that tried other surfactants have returned to CUROSURF, with 90% of hospitals returning within two years[1].

Clinical Usage and Dosing

CUROSURF is administered at an initial dose of 200 mg/kg (2.5 mL/kg), which is higher than the initial doses of other surfactants like Survanta (100 mg/kg) and Infasurf (105 mg/kg). This dosing regimen has been a factor in its widespread adoption due to its efficacy[1].

Safety and Efficacy

CUROSURF has a strong safety and efficacy profile, supported by over 25 years of worldwide clinical experience. It has been used to treat over 6 million infants globally, with a favorable safety record compared to other surfactants[1].

Financial Impact

The financial trajectory of CUROSURF is robust, reflecting its market dominance. While specific financial figures for CUROSURF are not publicly disclosed, its widespread adoption and high market share indicate significant revenue generation. The biologics market, in general, has seen substantial growth, with biologics now representing 42% of the total medicines market, up from 30% in 2014[3].

Market Exclusivity and Competition

Unlike small molecules, biologics like CUROSURF face different market exclusivity dynamics. The introduction of biosimilars can impact the market share of biologics, but CUROSURF's strong clinical profile and widespread adoption have helped it maintain its market position. By 2019, only 17% of the biologics market was accessible to biosimilars, and CUROSURF's unique formulation and clinical benefits have kept it ahead of potential biosimilar competition[3].

Hospital and Clinical Preferences

CUROSURF is preferred by many teaching hospitals and fellowship programs. In 87% of teaching hospitals using more than 100 mL of surfactant, CUROSURF has a more than 90% share. This preference is driven by its clinical efficacy and the trust placed in it by healthcare professionals[1].

Global Reach and Accessibility

The global availability of CUROSURF in 97 countries underscores its accessibility and demand. This widespread use is a testament to its effectiveness and the trust it has garnered among healthcare providers worldwide[1].

Industry Trends and Future Outlook

The biologics market is expected to continue growing, driven by advances in biotechnology and increasing demand for targeted therapies. As a leading biologic surfactant, CUROSURF is well-positioned to benefit from these trends. However, the market will also see increased competition from biosimilars and new biologic products, which could impact its market share in the future[3].

Key Statistics

  • Market Share: CUROSURF is used by over 85% of top neonatology hospitals in the United States[1].
  • Global Presence: Available in 97 countries[1].
  • Clinical Experience: Over 25 years of worldwide clinical experience and used to treat over 6 million infants[1].
  • Hospital Retention: 90% of hospitals return to CUROSURF after trying a different surfactant within two years[1].

Conclusion

CUROSURF's market dominance and financial trajectory are driven by its clinical efficacy, widespread adoption, and strong safety profile. As the biologics market continues to evolve, CUROSURF remains a leader in the treatment of RDS in premature infants.

Key Takeaways

  • CUROSURF is the leading surfactant in the United States and globally.
  • It has a strong safety and efficacy profile with over 25 years of clinical experience.
  • The drug is widely adopted by top neonatology hospitals and teaching institutions.
  • CUROSURF's market share is significant, with a high retention rate among hospitals.
  • The biologics market, including CUROSURF, is expected to continue growing despite potential competition from biosimilars.

FAQs

Q: What is CUROSURF used for? CUROSURF is used for the rescue treatment of Respiratory Distress Syndrome (RDS) in premature infants.

Q: How widely is CUROSURF used? CUROSURF is used by over 85% of top neonatology hospitals in the United States and is available in 97 countries worldwide.

Q: What is the initial dose of CUROSURF? The initial dose of CUROSURF is 200 mg/kg (2.5 mL/kg).

Q: Why do hospitals prefer CUROSURF? Hospitals prefer CUROSURF due to its clinical efficacy, strong safety profile, and high retention rate among healthcare providers.

Q: How does CUROSURF compare to other surfactants? CUROSURF has a higher initial dose compared to other surfactants like Survanta and Infasurf and is preferred by many hospitals due to its clinical benefits.

Sources

  1. Chiesi USA: CUROSURF Market Leader Insert.
  2. Michigan State University: Gift, Grant, and Contract Report.
  3. Federal Trade Commission: Biologics Market Dynamics: Setting the Stage for Biosimilars.

More… ↓

⤷  Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.